| Prev Close | 6.34 |
| Open | 6.35 |
| Day Low/High | 6.15 / 6.66 |
| 52 Wk Low/High | 4.95 / 12.73 |
| Volume | 303.87K |
| Exchange | NASDAQ |
| Shares Outstanding | 34.39M |
| Market Cap | 233.88M |
| Div & Yield | N.A. (N.A) |
Latest News
ACT Announces Positive Results From Two Clinical Trials Published In The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells For The Treatment Of Macular Degeneration
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative ophthalmology, announced today that Phase 1/2 clinical data published online in The Lancet demonstrate positive long-term...
Advanced Cell Technology Announces 1:100 Reverse Stock Split
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced that it has completed a 1:100 reverse split of its common stock.
Advanced Cell Technology To Host Conference Call To Provide A Corporate Update
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today will host a conference call on Monday, August 11, 2014 at 5:00 p.
Advanced Cell Technology Secures $30 Million Equity Facility From Lincoln Park Capital
Advanced Cell Technology, Inc. (“ACT”)(OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that it has entered into a $30 million common stock purchase agreement with Lincoln Park Capital...
Advanced Cell Technology, Inc. Announces Paul K. Wotton Ph.D. Recognized As Ernst & Young (EY) 2014 Entrepreneur Of The Year™ For New Jersey Region
Advanced Cell Technology, Inc. (“ACT”) (OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that Paul K.
Advanced Cell Technology Appoints Paul K. Wotton, Ph.D, President And Chief Executive Officer
Advanced Cell Technology, Inc. (“ACT”)(OTCBB:ACTC), a leader in the field of regenerative medicine, today announced the appointment of Paul Wotton, Ph.
Advanced Cell Technology To Host Conference Call To Provide A Corporate Update; Announces Settlement Of Litigation
Advanced Cell Technology, Inc. (“ACT” or “the Company”; OTC:ACTC), a leader in the field of regenerative medicine, announced today it will host a conference call on Monday, June 9, 2014 at 5:00 p.
Advanced Cell Technology’s Chief Scientific Officer Dr. Robert Lanza Named One Of TIME Magazine’s 100 Most Influential People In The World
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company’s Chief Scientific Officer, Robert Lanza, MD, has been selected for the 2014 ...
Advanced Cell Technology To Host Conference Call To Provide A Corporate Update
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that it filed its annual report on Form 10-K for the year ended December 31, 2013.
New Mesenchymal Stem Cell Population From Human Pluripotent Stem Cells Displays Potent Immunomodulatory And Therapeutic Properties
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, and its collaborators reported today that it has discovered a new method to generate a potent and replenishable...
Advanced Cell Technology To Present At Regenenerative Medicine Investor Day March 26, 2014
Advanced Cell Technology (ACTC) today announced that Edward Myles, Interim President, CFO & EVP of Corporate Development, will present at the 2 nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014...
Advanced Cell Technology Announces Change In Management
Advanced Cell Technology (OTC:ACTC) today announced that Gary Rabin will leave the Chief Executive Officer position, effective immediately.
Advanced Cell Technology Announces Release Of New Edition Of Definitive Resource In Tissue Engineering
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.
Advanced Cell Technology Appoints Eddy Anglade M.D. Executive Vice President Of Clinical Development
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, today announced the appointment of Eddy Anglade, M.
Advanced Cell Technology Announces 2013 Third Quarter Results
Advanced Cell Technology, Inc. (“ACT”; OTC:ACTC or the “Company”), a leader in the field of regenerative medicine, announced today third quarter financial results for the period ended September 30,...
Advanced Cell Technology To Host Conference Call To Discuss 2013 Third Quarter Results And Provide A Corporate Update On Tuesday, November 12th
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that it will release its third quarter financial results for the period ended ...
ACT’s Dr. Robert Lanza To Deliver Keynote Lecture At The World Conference On Regenerative Medicine
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.
Advanced Cell Technology To Webcast 2013 Annual Shareholders’ Meeting On Tuesday, October 22nd
Advanced Cell Technology, Inc. (“ACT”)(OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will webcast its Annual Shareholders’ Meeting to be held on Tuesday, October 22nd...
Advance Cell Technology To Present At 2013 Aegis Capital Healthcare Conference
Advanced Cell Technology, Inc. (“ACT”; OTCQB:ACTC), a leader in the field of regenerative medicine, today announced that Chairman and CEO Gary Rabin will present a corporate overview at the 2013 Aegis...
ACT’s Dr. Robert Lanza To Receive The Il Leone Di San Marco Award In Medicine
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that the company’s Chief Scientific Officer, Robert Lanza, MD, has been nominated to receive the ...
ACT Files Investigational New Animal Drug (INAD) Application With FDA To Treat 10 Different Disease Indications Using Pluripotent Stem Cells
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has filed an Investigational New Animal Drug (INAD) application with the Food and Drug...
Advanced Cell Technology Files Preliminary Proxy Statement With Securities And Exchange Commission
Advanced Cell Technology, Inc. (“ACT”; OTCQB: ACTC), a leader in the field of regenerative medicine, announced that it has filed preliminary proxy materials with the Securities and Exchange Commission...
Advanced Cell Technology Announces Second Quarter 2013 Results
Advanced Cell Technology, Inc. (“ACT”; OTCQB: ACTC), a leader in the field of regenerative medicine, announced today second quarter financial results for the period ended June 30, 2013.
Advanced Cell Technology To Host Conference Call To Discuss 2013 Second Quarter Results And Provide A Corporate Update On Wednesday, August 7th
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will release its second quarter financial results for the period ended June 30,...
ACT Secures Approval From Data Safety Monitoring Board To Complete Third Patient Cohort In All Three Clinical Trials
Advanced Cell Technology, Inc. (“ACT”) (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts...
Advanced Cell Technology, Cytomedix And Mesoblast To Provide Corporate And Clinical Updates At Regen Med Investor Day
- Alliance for Regenerative Medicine Announces Final Disease Session Panelists; 16 leading regenerative medicine companies discuss late stage and commercial products -
ACT’s Chief Scientific Officer Dr. Robert Lanza To Deliver The Nerem Lecture 2013 At The 17th Annual Hilton Head Workshop
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.
Advanced Cell Technology Receives Approval From Data Safety Monitoring Board (DSMB) To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the independent Data and Safety Monitoring Board (DSMB) overseeing the Company’s three ...